This, in conjunction with the observation from the in silico screen that suggests reduced mRNA expression of TMPRSS2 in cells exposed to selumetinib, identifies the MEK inhibitor as a plausible candidate for further evaluation in experimental models relevant to COVID-19. Here, TMPRSS2 is linked to COVID-19.